Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
APTO has been the subject of several other research reports. HC Wainwright set a $6.00 price objective on shares of Lorus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 28th. ValuEngine lowered shares of Lorus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $5.38.
Lorus Therapeutics stock opened at $3.05 on Thursday. Lorus Therapeutics has a 52-week low of $0.78 and a 52-week high of $3.97. The firm has a market capitalization of $97.02, a PE ratio of -5.87 and a beta of 2.32.
An institutional investor recently raised its position in Lorus Therapeutics stock. Acadian Asset Management LLC increased its position in Lorus Therapeutics, Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the quarter. Acadian Asset Management LLC owned 0.17% of Lorus Therapeutics worth $100,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/zacks-investment-research-downgrades-lorus-therapeutics-apto-to-hold.html.
Lorus Therapeutics Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.